Clinical Cancer Research CR Surrogrates Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 3499, June 15, 2007. doi: 10.1158/1078-0432.CCR-07-0237
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peddinti, R.
Right arrow Articles by Cohn, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peddinti, R.
Right arrow Articles by Cohn, S. L.

Human Cancer Biology

Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma

Radhika Peddinti1, Rana Zeine2, Dragos Luca5, Roopa Seshadri1, Alexandre Chlenski2, Kristina Cole4, Bruce Pawel4, Helen R. Salwen2, John M. Maris4 and Susan L. Cohn3

Authors' Affiliations: 1 Department of Pediatrics, Children's Memorial Hospital; 2 Robert H. Lurie Comprehensive Cancer Center, Northwestern University; 3 Institute for Molecular Pediatric Sciences, University of Chicago, Chicago, Illinois; 4 Department of Pediatrics, Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and 5 Department of Pathology, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota

Requests for reprints: Susan L. Cohn, Clinical Sciences, Institute for Molecular Pediatric Sciences, University of Chicago, 5841 Maryland Avenue, MC 4060, Room N114, Chicago, IL 60637. Phone: 773-702-2571; Fax: 773-834-1329; E-mail: scohn{at}peds.bsd.uchicago.edu.

Purpose: Tumor vasculature is disorganized and glomeruloid microvascular proliferation (MVP) has been identified as a poor prognosticator in some adult cancers. To determine the clinical significance of MVP, including glomeruloid MVP in neuroblastoma, we initially examined vessel architecture in tumor sections from 51 children diagnosed at Children's Memorial Hospital (CMH) and subsequently evaluated 154 neuroblastoma tumors on a tissue microarray constructed at Children's Hospital of Philadelphia (CHOP).

Experimental Design: H&E sections were examined for the presence of structurally abnormal vessels and further characterized by immunostaining for CD31 and von Willebrand factor to highlight endothelial cells and {alpha}-smooth muscle actin for pericytes. Tumors with thickened walls containing a complete layer of hypertrophic endothelial cells plus additional layers of vascular mural cells were classified as MVP positive. Associations between MVP and established clinicopathologic features and outcome were assessed.

Results: In both series, MVP was significantly associated with Schwannian stroma-poor histology (CMH, P = 0.008; CHOP, P < 0.001) and decreased survival probability (CMH, P = 0.017; CHOP, P = 0.014). In the CHOP series, MVP was associated with high-risk group classification (P < 0.001), although this association was not seen in the smaller CMH cohort.

Conclusions: The association between MVP and poor outcome provides further support for the concept that angiogenesis plays an important role in determining the biological behavior of neuroblastoma tumors. Our results also indicate that angiogenesis is regulated differently in Schwannian stroma-rich versus stroma-poor neuroblastoma tumors. Further studies investigating the activity of angiogenic inhibitors in children with clinically aggressive stroma-poor neuroblastoma are warranted.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
F. Pastorino, D. Di Paolo, F. Piccardi, B. Nico, D. Ribatti, A. Daga, G. Baio, C. E. Neumaier, C. Brignole, M. Loi, et al.
Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin
Clin. Cancer Res., November 15, 2008; 14(22): 7320 - 7329.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. M. Guo, J. Sheng, G. M. Scicli, A. S. Arbab, N. L. Lehman, P. A. Edwards, J. R. Falck, R. J. Roman, and A. G. Scicli
Expression of CYP4A1 in U251 Human Glioma Cell Induces Hyperproliferative Phenotype in Vitro and Rapidly Growing Tumors in Vivo
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 10 - 19.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.